Treating psychological conditions using muscarinic receptor M
Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M 1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M 1 antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M 1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M 1 antagonist.
1. A method for enhancing the antidepressant effect of an antidepressant selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), the method comprising systemically co-administering to an individual in need thereof telenzepine and a SSRI or a SNRI selected from the group consisting of venlafaxine, sertraline and fluoxetine in a therapeutically effective amount to treat depression, thereby enhancing the antidepressant effect of the SSRI or the SNRI.
2. The method of claim 1 , wherein the SSRI is fluoxetine.
3. The method of claim 1 , wherein the SSRI is sertraline.
4. The method of claim 1 , wherein the SNRI is venlafaxine.
5. The method of claim 1 , wherein the telenzepine is administered in a sustained-release formulation.
6. An improved method for treating depression with an antidepressant selected from the group consisting of a SSRI or an SNRI, the improvement comprising systemically co-administering to an individual in need thereof telenzepine and a SSRI or a SNRI selected from the group consisting of venlafaxine, sertraline and fluoxetine in a therapeutically effective amount to treat depression.
7. The method of claim 6 , wherein the SSRI is fluoxetine.
8. The method of claim 6 , wherein the SSRI is sertraline.
9. The method of claim 6 , wherein the SNRI is venlafaxine.
10. The method of claim 6 , wherein the telenzepine is administered in a sustained-release formulation.